KMT5A and neoplasm: Since SET8 has been implicated in the developmentof a variety of cancers and the widespread use of cisplatin as a chemotherapeutic agent formost solid tumors, but with known nephrotoxicity, the results from this study suggest thatcombined administration of SET8 inhibitors with cisplatin could enhance tumor eradicationwhile simultaneously protecting against AKI.